经导管主动脉瓣置换术治疗单纯原生主动脉瓣反流
该多中心注册研究纳入331例有症状的单纯原生主动脉瓣反流患者,比较早期与新型器械行TAVR的结局。新型器械器械成功率更高(81.1% vs 61.3%,P<0.001),术后反流≥中度更少(4.2% vs 18.8%,P<0.001);术后反流≥中度与1年全因死亡独立相关(HR 2.85,95%CI 1.52–5.35,P=0.001)。
要点
- 新型器械较早期器械提高器械成功率并减少术后显著反流。
- 术后反流≥中度者1年全因死亡率显著高于反流≤轻度者。
- 术后反流≥中度是1年全因死亡的独立危险因素。
核心结论
- 与早期器械相比,使用新型器械行TAVR治疗单纯原生主动脉瓣反流可改善手术结局。
- 术后显著反流与单纯原生主动脉瓣反流患者死亡率增加独立相关。
研究设计与样本
- 基于单纯原生主动脉瓣反流TAVR多中心注册研究,按VARC-2标准评估手术与临床结局。
- 共331例有症状患者接受TAVR,平均STS评分6.7±6.7。
- 早期器械组119例(36.0%),新型器械组212例(64.0%)。
主要发现
- 新型器械组器械成功率显著高于早期器械组(81.1% vs 61.3%,P<0.001)。
- 新型器械组二次瓣膜植入率较低(12.7% vs 24.4%,P=0.007)。
- 新型器械组术后反流≥中度发生率较低(4.2% vs 18.8%,P<0.001)。
- 两组30天主要终点无显著差异。
- 1年全因死亡与心血管死亡累积率分别为24.1%和15.6%。
关键数值与推荐
- 术后反流≥中度者1年全因死亡率为46.1%,反流≤轻度者为21.8%(log-rank P=0.001)。
- 多变量分析显示术后反流≥中度与1年全因死亡独立相关(HR 2.85,95%CI 1.52–5.35,P=0.001)。
- 早期器械组经股动脉入路使用率高于新型器械组(87.4% vs 60.8%,P<0.001)。
- 新型器械组STS评分有低于早期器械组的趋势(6.2±6.7 vs 7.6±6.7,P=0.08)。
临床怎么用
- 在单纯原生主动脉瓣反流患者中优先考虑使用新型TAVR器械以提高器械成功率。
- 术后应积极评估并尽量避免反流≥中度,以降低远期死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited data exist about safety and efficacy of transcatheter aortic valve replacement (TAVR) in patients with pure native aortic regurgitation (AR). OBJECTIVES: This study sought to compare the outcomes of TAVR with early- and new-generation devices in symptomatic patients with pure native AR. METHODS: From the pure native AR TAVR multicenter registry, procedural and clinical outcomes were assessed according to VARC-2 criteria and compared between early- and new-generation devices. RESULTS: A total of 331 patients with a mean STS score of 6.7 ± 6.7 underwent TAVR. The early- and new-generation devices were used in 119 patients (36.0%) and 212 patients (64.0%), respectively. STS score tended to be lower in the new-generation device group (6.2 ± 6.7 vs. 7.6 ± 6.7; p = 0.08), but transfemoral access was more frequently used in the early-generation device group (87.4% vs. 60.8%; p < 0.001). Compared with the early-generation devices, the new-generation devices were associated with a significantly higher device success rate (81.1% vs. 61.3%; p < 0.001) due to lower rates of second valve implantation (12.7% vs. 24.4%; p = 0.007) and post-procedural AR ≥ moderate (4.2% vs. 18.8%; p < 0.001). There were no significant differences in major 30-day endpoints between the 2 groups. The cumulative rates of all-cause and cardiovascular death at 1-year follow-up were 24.1% and 15.6%, respectively. The 1-year all-cause mortality rate was significantly higher in the patients with post-procedural AR ≥ moderate compared with those with post-procedural AR ≤ mild (46.1% vs. 21.8%; log-rank p = 0.001). On multivariable analysis, post-procedural AR ≥ moderate was independently associated with 1-year all-cause mortality (hazard ratio: 2.85; 95% confidence interval: 1.52 to 5.35; p = 0.001). CONCLUSIONS: Compared with the early-generation devices, TAVR using the new-generation devices was associated with improved procedural outcomes in treating patients with pure native AR. In patients with pure native AR, significant post-procedural AR was independently associated with increased mortality.
引用
- Yoon SH, Schmidt T, Bleiziffer S, et al. Transcatheter Aortic Valve Replacement in Pure Native Aortic Valve Regurgitation. J Am Coll Cardiol. 2017. PMID: 29191323. doi:10.1016/j.jacc.2017.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。